阿拉伯聯合大公國杜拜--(BUSINESS WIRE)--十二月 20, 2024--
(美國商業資訊)-- 全球最大的金融衍生品機構、總部位於杜拜的MultiBank Group因其對產業的貢獻而在2024年香港貿易展覽會上獲得肯定。該公司榮獲三項殊榮：「2024年全球最佳外匯合作夥伴計畫」、「菲律賓最佳外匯經紀商」和「年度外匯經紀商」。
本新聞稿包含多媒體資訊。完整新聞稿請見此： https://www.businesswire.com/news/home/20241219104371/zh-HK/
香港貿易展覽會是亞洲首屈一指的金融盛會，聚集了來自世界各地的數千名交易者、投資人和業界專業人士。該平台展示了塑造全球金融市場的最新趨勢、科技和策略。集團在此次活動中獲得的肯定彰顯了其在提供頂尖金融服務方面追求卓越和創新的承諾。
「2024年全球最佳外匯合作夥伴計畫」獎反映了該機構透過提供業界首屈一指的工具、資源和成功激勵措施來建立牢固合作夥伴關係的能力。另外兩個獎項——「菲律賓最佳外匯經紀商」和「年度外匯經紀商」——進一步鞏固了公司在不同市場提供卓越服務的聲譽。
MultiBank Group創辦人兼董事長Naser Taher對這一成就感到驕傲，他表示：「我們非常榮幸能夠在2024年香港貿易展覽會上獲得這些獎項。它們反映了我們重新定義產業標準和提升客戶體驗的決心。在MultiBank Group，我們致力於創新、可靠性和提供最高水準的服務。」
該集團擁有由超過2萬種金融工具組成的產品組合，涵蓋外匯、金屬、商品、股票、指數和數位資產，為客戶提供多樣化的交易選擇。在先進的交易平台、卓越的流動性和多司法管轄區監管的支援下，集團致力於確保安全、透明和順暢的交易體驗。
MultiBank Group成立於2005年，如今為100個國家的逾100萬客戶提供服務，管理的日交易量超過181億美元。MultiBank Group在全球各主要金融中心設有辦事處，已獲得70多個金融獎項，奠定了其做為全球金融業值得信賴的領導者的地位。
關於MULTIBANK GROUP
MultiBank Group於2005年在美國加州成立，是金融衍生品領域的全球領導者，為100個國家的超過100萬客戶提供服務，日交易量超過181億美元。該集團以其創新的交易解決方案、嚴格的法規遵循和卓越的客戶服務而著稱，提供廣泛的經紀服務和資產管理解決方案。它在五大洲受到全球超過16家最負盛名的金融機構的監管。集團屢獲殊榮的交易平台就多樣化的產品提供高達500:1的槓桿，包括外匯、金屬、股票、商品、指數和加密貨幣。MultiBank Group已獲得超過65個金融獎項，以表揚其卓越的交易服務和法規遵循。如欲瞭解更多資訊，請造訪MultiBank Group的 網站 。
免責聲明：本公告之原文版本乃官方授權版本。譯文僅供方便瞭解之用，煩請參照原文，原文版本乃唯一具法律效力之版本。
請前往 businesswire.com 瀏覽源版本:https://www.businesswire.com/news/home/20241219104371/zh-HK/
CONTACT: Yazan Shakfeh
Mohammad.shakfeh@multibankfx.com
00971585754191
KEYWORD: UNITED ARAB EMIRATES ASIA PACIFIC MIDDLE EAST
INDUSTRY KEYWORD: PROFESSIONAL SERVICES OTHER PROFESSIONAL SERVICES FINANCE FINTECH ASSET MANAGEMENT BANKING
SOURCE: MultiBank Group
Copyright Business Wire 2024.
PUB: 12/20/2024 06:16 AM/DISC: 12/20/2024 06:17 AM
http://www.businesswire.com/news/home/20241219104371/zh
MultiBank Group在香港貿易展覽會上榮獲三項大獎（圖片：美國商業資訊）
ZÜRICH--(BUSINESS WIRE)--Dec 20, 2024--
Bruker announces the acceptance of a 1.2 GHz Ascend™ Nuclear Magnetic Resonance (NMR) spectrometer at the Swiss High-field NMR Facility, operated jointly by the University of Basel, ETH Zürich, and the University of Zürich. This state-of-the-art instrument will significantly enhance the research capabilities of several user groups, enabling advanced studies in structural biology and macromolecular analysis. The instrument, located at the University of Zürich, is the second 1.2 GHz NMR in Switzerland, with the first at ETH used for developing solid-state NMR techniques, and studying materials and biological systems.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241220748125/en/
The Swiss High-field NMR Facility has locations at Biozentrum Basel and at University of Zürich. The new 1.2 GHz NMR complements the existing 800 MHz NMR in Basel and other high-field NMRs for protein structure determination, measurement of protein dynamics, ligand binding studies, conformational fingerprinting, and the analysis of protein-protein interactions.
Professor Oliver Zerbe from University of Zürich stated: "The 1.2 GHz NMR enables the study G protein-coupled receptors (GPCRs) in greater detail to define dynamic behavior and conduct drug binding studies. The higher resolution and dispersion at 1.2 GHz enhance the study of interactions of drug candidates with GPCRs. Professor Ricarda Törner, who will join UZH in 2025, will greatly benefit from increased resolution in her studies of intrinsically disordered proteins. Similarly, Professor Sigel's group anticipates significant advantages for their RNA research."
Stephan Grzesiek, Professor of Structural Biology at Biozentrum Basel, who started the initiative for a Swiss high-field solution NMR, remarked: “Finally, we also have a highest-field NMR available for Swiss solution NMR. It will enable new NMR methods and explore the limits of detection in disease-relevant applications, such as GPCR signaling and cancer.”
His colleague, Professor Sebastian Hiller from Biozentrum Basel noted: "The 1.2 GHz NMR allows to study structures and dynamics of chaperone-client complexes at atomic resolution. These detailed descriptions will reveal biophysical laws governing chaperone function, with implications for neurodegenerative diseases, such as Parkinson’s."
Detlef Günther, Professor for Trace Element and Micro Analysis, and Vice President of Research at ETH Zürich (2015-2022) when the instrument was ordered, remarked: "We are excited to provide our scientists with this ultra-high field NMR. This collaboration will enable groundbreaking research in structural biology, furthering our understanding of complex biological systems.”
About Bruker Corporation – Leader of the Post-Genomic Era (Nasdaq: BRKR)
Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit www.bruker.com.
New 1.2 GHz Avance® at UZH site of the Swiss High-Field NMR Facility (Photo: Business Wire)
